Silicon Therapeutics (“SITX”) is a privately held, physics-driven integrated drug discovery company in the preclinical IND stage targeting innate immunity to start, but with the capability to move into many other franchise opportunities. The Company’s initial pipeline is focused on modulation of the innate immune system to “light the spark” within immunologically cold tumors by using its physics-enabled drug discovery engine for the design of small molecule therapeutics and the lead program is in late stage preclinical studies. SITX’s discovery efforts as well as physics-based platform are all completely in-house, with a full wet lab as well as a team of over 25 experienced R&D professionals spanning biology, biochemistry, chemistry, biophysics (NMR + X-ray) & preclinical sciences. SITX’s engine leverages quantum mechanics and molecular dynamics, which are deployed on its own internal supercomputer composed of over 400 GPU’s and FPGA’s and allows SITX to accurately simulate the physical motion and properties of biological targets at an atomistic level resolution. The platform is completely proprietary to SITX and was built from the ground up with the purpose of addressing difficult targets and using simulations to break through bottlenecks that has plagued traditional drug discovery approaches on such targets. It is currently the ONLY company which owns the entire spectrum of physics-driven drug discovery from chip-to-clinic with a team of over 40 individuals in Boston.
The Company’s initial focus in on innate immunity and its pipeline is currently composed of one project entering IND-enabling studies, another one entering hit-to-lead and two more ramping up. It’s unique advantage in designing small molecules using all atom simulations has allowed it to advance a systemically available small molecule STING agonist into a preclinical development. The program is ramping up for IND enabling studies entry to the clinic in 2020. This differentiated product can be administered systemically via an IV dose and has single agent effects in early mouse efficacy studies using PD1 resistant tumor models and is a “rule-of-5” compliant small molecule. Beyond this one program, the Company is also advancing an ADAR inhibitor which can be considered an innate immune checkpoint as well as a multitude of targets that explore Innate Immunity’s role in cancer biology.
• Serve as medicinal chemistry lead for internal drug discovery projects and drive to clear decision points to ensure timeline adherence and project alignment with company goals.
• Prioritize medicinal chemistry activities, managing both internal and external chemistry resources to ensure timeline adherence and project alignment with company goals.
• Work intimately within the chemistry and computational design group to evaluate and prioritize new compound designs in weekly design meetings.
• Establish and maintain a clear understanding of the internal computational capabilities, and how to apply these tools to support new compound design.
• Build, critically interpret and react to structure activity relationships incorporating structural information and physicochemical properties.
• Possess a clear and effective communication style to disseminate project data and medicinal chemistry approach to both internal colleagues and external collaborators
• Build and maintain productive relationships with cross functional colleagues in computational simulation, computational development and structural biology and biophysics.